Stereotaxis Closes Robocath Acquisition, Expanding Surgical Robotics

Stereotaxis (NYSE: STXS), a St. Louis-based robotics company known for pushing the boundaries of minimally invasive endovascular surgery, has officially closed its acquisition of French innovator Robocath. The deal, which had been previously announced, crossed the finish line on July 9, 2026, marking a significant step forward for both companies.

If you're not deep in the medical device world, here's the quick translation: endovascular procedures are surgeries performed from inside your blood vessels — think threading a tiny catheter through your arteries rather than cracking open your chest. Stereotaxis has built its reputation on making those procedures more precise using surgical robots, and Robocath brings complementary robotics chops focused specifically on interventional cardiology and neurointerventions (that's brain and nervous system stuff, for the uninitiated).

Read more Taco Bell Pulls Produce Amid Michigan Parasite Outbreak →

Robocath, headquartered in Rouen, France, has been developing robotic systems aimed at making catheter-based heart and brain procedures safer and more consistent. By folding Robocath's technology under its roof, Stereotaxis is essentially doubling down on its bet that robots are the future of these delicate, high-stakes medical interventions — a market that has been drawing serious investor and clinical attention in recent years.

For shareholders and healthcare watchers alike, the completed acquisition signals that Stereotaxis is moving aggressively to broaden its product footprint beyond its existing platform. Whether the combined company can translate that expanded toolkit into revenue growth and clinical adoption will be the real story to follow in the months ahead. The pairing of a US-listed robotics leader with a European cardiology and neuro-focused innovator could also open doors to new geographic markets and clinical partnerships.

Continue reading at GlobalNewswire.